Jimmy J. Hwang
YOU?
Author Swipe
View article: Role of <i>CD47</i> gene expression in colorectal cancer: a comprehensive molecular profiling study
Role of <i>CD47</i> gene expression in colorectal cancer: a comprehensive molecular profiling study Open
Background In patients with colorectal cancer (CRC), the therapeutic effects of conventional immune checkpoint inhibitors targeting the adaptive immune system are largely limited to those with microsatellite instability-high tumors. Meanwh…
View article: Large-scale analysis of CDH1 mutations defines a distinctive molecular subset with treatment implications in gastric cancer
Large-scale analysis of CDH1 mutations defines a distinctive molecular subset with treatment implications in gastric cancer Open
Although histological and molecular classifications have been extensively studied for gastric cancer (GC), targeted therapies for GC remain limited. CDH1 mutations (MT) are characteristic of genomically stable GC and are associated with po…
View article: Phase II trial of pembrolizumab, ipilimumab, and aspirin in melanoma: clinical outcomes and translational predictors of response
Phase II trial of pembrolizumab, ipilimumab, and aspirin in melanoma: clinical outcomes and translational predictors of response Open
Objective Many patients with melanoma treated with immune checkpoint inhibitors (ICIs) do not derive response. Preclinical and retrospective studies identified that inhibition of the cyclooxygenase (COX) pathway may improve response to ICI…
View article: Real-World Impact of an In-House Dihydropyrimidine Dehydrogenase (<i>DPYD</i>) Genotype Test on Fluoropyrimidine Dosing, Toxicities, and Hospitalizations at a Multisite Cancer Center
Real-World Impact of an In-House Dihydropyrimidine Dehydrogenase (<i>DPYD</i>) Genotype Test on Fluoropyrimidine Dosing, Toxicities, and Hospitalizations at a Multisite Cancer Center Open
PURPOSE Fluoropyrimidine-related toxicity and mortality risk increases significantly in patients carrying certain DPYD genetic variants with standard dosing. We implemented DPYD genotyping at a multisite cancer center and evaluated its imp…
View article: Predicting response to neoadjuvant chemotherapy for colorectal liver metastasis using deep learning on prechemotherapy cross‐sectional imaging
Predicting response to neoadjuvant chemotherapy for colorectal liver metastasis using deep learning on prechemotherapy cross‐sectional imaging Open
Background and Objectives Deep learning models (DLMs) are applied across domains of health sciences to generate meaningful predictions. DLMs make use of neural networks to generate predictions from discrete data inputs. This study employs …
View article: Supplementary Figure Legend from Association of Homologous Recombination–DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers
Supplementary Figure Legend from Association of Homologous Recombination–DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers Open
Supplementary Figure Legend
View article: Data from Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers
Data from Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers Open
The efficacy of immunotherapy varies widely among different gastrointestinal cancers. Response to immune checkpoint inhibitors is shown to correlate with tumor mutation load (TML), mismatch repair deficiency (dMMR) status, and programmed c…
View article: Table S1 from Molecular Characterization of Appendiceal Goblet Cell Carcinoid
Table S1 from Molecular Characterization of Appendiceal Goblet Cell Carcinoid Open
Comparison of mutation frequency between ex-GCC and pure GCC
View article: Table S1 from Molecular Characterization of Appendiceal Goblet Cell Carcinoid
Table S1 from Molecular Characterization of Appendiceal Goblet Cell Carcinoid Open
Comparison of mutation frequency between ex-GCC and pure GCC
View article: Data from Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers
Data from Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers Open
The efficacy of immunotherapy varies widely among different gastrointestinal cancers. Response to immune checkpoint inhibitors is shown to correlate with tumor mutation load (TML), mismatch repair deficiency (dMMR) status, and programmed c…
View article: Supplemental Figure 1 from Association of Homologous Recombination–DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers
Supplemental Figure 1 from Association of Homologous Recombination–DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers Open
Supplemental Figure 1
View article: Figure S3 from Molecular Characterization of Appendiceal Goblet Cell Carcinoid
Figure S3 from Molecular Characterization of Appendiceal Goblet Cell Carcinoid Open
MCP-counter results for the three appendiceal tumor groups
View article: Supplementary appendix from Molecular Characterization of Appendiceal Goblet Cell Carcinoid
Supplementary appendix from Molecular Characterization of Appendiceal Goblet Cell Carcinoid Open
The methods in assessing microsatellite instability (MSI) and mismatch repair (MMR) status
View article: Figure S1 from Molecular Characterization of Appendiceal Goblet Cell Carcinoid
Figure S1 from Molecular Characterization of Appendiceal Goblet Cell Carcinoid Open
TNM staging summary
View article: Supplementary Table S3 from Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers
Supplementary Table S3 from Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers Open
Published immune checkpoint inhibitor (ICI) response rate in gastrointestinal cancers.
View article: Supplementary Table S1 from Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers
Supplementary Table S1 from Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers Open
PD-L1 expression frequency comparison between MSI-H and MSS tumors.
View article: Supplementary Figure 2 from Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC
Supplementary Figure 2 from Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC Open
Quantitative CD8+ Counts in patients with Liver and skin metastases.
View article: Supplementary Figure Legend from Association of Homologous Recombination–DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers
Supplementary Figure Legend from Association of Homologous Recombination–DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers Open
Supplementary Figure Legend
View article: Data from Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC
Data from Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC Open
We explored the association between liver metastases, tumor CD8+ T-cell count, and response in patients with melanoma or lung cancer treated with the anti-PD-1 antibody, pembrolizumab. The melanoma discovery cohort was drawn fro…
View article: Supplementary Figure 2 from Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC
Supplementary Figure 2 from Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC Open
Quantitative CD8+ Counts in patients with Liver and skin metastases.
View article: Data from Basal Cell Carcinoma Chemoprevention with Nonsteroidal Anti-inflammatory Drugs in Genetically Predisposed <i>PTCH1</i><sup>+/−</sup> Humans and Mice
Data from Basal Cell Carcinoma Chemoprevention with Nonsteroidal Anti-inflammatory Drugs in Genetically Predisposed <i>PTCH1</i><sup>+/−</sup> Humans and Mice Open
In vitro and epidemiologic studies favor the efficacy of nonsteroidal anti-inflammatory drugs (NSAID) in preventing skin squamous photocarcinogenesis, but there has been relatively little study of their efficacy in preventing the mo…
View article: Table S2 from Molecular Characterization of Appendiceal Goblet Cell Carcinoid
Table S2 from Molecular Characterization of Appendiceal Goblet Cell Carcinoid Open
Copy number alteration frequency in appendiceal adenocarcinoma, NET and GCC
View article: Data from Molecular Characterization of Appendiceal Goblet Cell Carcinoid
Data from Molecular Characterization of Appendiceal Goblet Cell Carcinoid Open
Goblet cell carcinoid (GCC) is a distinct subtype of appendiceal neoplasm that exhibits unique clinical and pathologic features. We aimed to reveal the molecular profiles of GCC compared with other appendiceal tumors, such as adenocarcinom…
View article: Supplemental Figure 1 from Association of Homologous Recombination–DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers
Supplemental Figure 1 from Association of Homologous Recombination–DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers Open
Supplemental Figure 1
View article: Supplementary Table S1 from Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers
Supplementary Table S1 from Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers Open
PD-L1 expression frequency comparison between MSI-H and MSS tumors.
View article: Supplementary Table S3 from Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers
Supplementary Table S3 from Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers Open
Published immune checkpoint inhibitor (ICI) response rate in gastrointestinal cancers.
View article: Supplementary appendix from Molecular Characterization of Appendiceal Goblet Cell Carcinoid
Supplementary appendix from Molecular Characterization of Appendiceal Goblet Cell Carcinoid Open
The methods in assessing microsatellite instability (MSI) and mismatch repair (MMR) status
View article: Data from Association of Homologous Recombination–DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers
Data from Association of Homologous Recombination–DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers Open
The prevalence of homologous recombination–DNA damage response (HR-DDR) genetic alterations is of therapeutic interest in gastroesophageal cancers. This study is a comprehensive assessment of HR-DDR mutation prevalence across gastroesophag…
View article: Figure S2 from Molecular Characterization of Appendiceal Goblet Cell Carcinoid
Figure S2 from Molecular Characterization of Appendiceal Goblet Cell Carcinoid Open
Detected gene mutations and pathway-specific mutations in GCC
View article: Figure S3 from Molecular Characterization of Appendiceal Goblet Cell Carcinoid
Figure S3 from Molecular Characterization of Appendiceal Goblet Cell Carcinoid Open
MCP-counter results for the three appendiceal tumor groups